Structured around the ongoing development of a high intensity ultrasound-aided laser thermal ablation system initially tackled by one the firm's founders at University of Michigan. The effort is to bring to use-condition a new, noninvasive therapeutic technique for safe and efficient treatment of choroidal neovascularization (CNV) in patients with wet AMD - the leading cause of irreversible blindness in the developed world. Anti-VEGF therapy is currently the gold standard for wet AMD treatment. However, over the long haul a high percentage of patients have a sub-optimal response to anti-VEGF therapy indicating an alternative method for treatment of AMD is urgently needed. Principals of ther firm indicate having recently invented a novel, effective, and highly-selective anti- vascular therapy, termed “photo-mediated ultrasound therapy (PUT)."
